MiMedx schedules October 28 results. Analysts set a USD 8.57 target for MiMedx stock

Published on 10/16/2026 at 03:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 64.36 million against USD 63.46 million estimates. Seven analysts rated MiMedx stock Moderate Buy on October 6, 2026.

Results date and analyst view

MiMedx scheduled its third-quarter results for October 28, 2026, with a 4:30 p.m. Eastern Time webcast.
Second-quarter revenue reached USD 64.36 million versus USD 63.46 million in estimates.
MarketBeat reported a Moderate Buy consensus from seven analysts on October 6, 2026.
The average 12-month price target was USD 8.57 on October 6, 2026.

MDXG, US6024961012, Illustration mit AI erstellt.

MiMedx Group stock (ISIN US6024961012) is heading toward its next results date after the company scheduled a third-quarter report for October 28, 2026. The release says the webcast will begin at 4:30 p.m. Eastern Time after the market close, giving investors a defined date for the next operating update.

October 28 results set the next test

According to MIMEDX on October 14, 2026, the third-quarter results will cover the period ended September 30, 2026. Management will review the figures during the same-day webcast and conference call.

The upcoming report follows second-quarter revenue of USD 64.36 million for the period ended June 30, 2026. That result was above the USD 63.46 million analyst estimate, a USD 0.90 million difference, while diluted earnings per share were negative USD 0.10.

What does the analyst view imply?

MarketBeat reported on October 6, 2026, that seven analysts held a Moderate Buy consensus, with six buy ratings and one sell rating. The average 12-month price target was USD 8.57, while the latest reported quarterly loss was USD 0.05 per share on an adjusted basis.

The analyst view therefore centers on execution rather than a new corporate transaction. The October report can clarify whether surgical demand offsets pressure in other wound-care activities and whether revenue growth is translating into improved earnings.

Three dated signals for MDXG

On July 29, 2026, MiMedx reported second-quarter revenue of USD 64.36 million. On October 6, 2026, MarketBeat cited seven analysts and an average USD 8.57 target. On October 14, 2026, MiMedx announced the October 28 results date and the 4:30 p.m. Eastern Time webcast.

Next date for investors

The next scheduled company event is the third-quarter operating and financial results webcast on October 28, 2026, at 4:30 p.m. Eastern Time.

Market value and business context

MiMedx develops and markets human placental tissue allografts for wound care, surgery and orthopedic applications. Its market capitalization was USD 682.2 million as of October 15, 2026, while the 52-week range was USD 3.03 to USD 7.97 in the October 6, 2026 market overview.